Metabolic Syndrome Components in Patients with Pituitary Adenoma.

Autor:	Gonzalez-Almazan JA; Research Division, General Hospital of Mexico, Ciudad de Mexico, Mexico.; Functional & Stereotactic Neurosurgery Unit, General Hospital of Mexico, Ciudad de Mexico, Mexico.; Facultad de Estudios Superiores Iztacala, Universidad Nacional Autonoma de Mexico Facultad de Estudios Superiores Iztacala, Tlalnepantla, Mexico., Cortes-Contreras AP; Research Division, General Hospital of Mexico, Ciudad de Mexico, Mexico.; Functional & Stereotactic Neurosurgery Unit, General Hospital of Mexico, Ciudad de Mexico, Mexico.; Faculty of Medicine, National Autonomous University of Mexico, Ciudad de Mexico, Mexico., Flores-Rabasa R; Research Division, General Hospital of Mexico, Ciudad de Mexico, Mexico.; Faculty of Health Sciences, Anahuac University Mexico - Southern Campus, Ciudad de Mexico, Mexico., Mendez-Garcia LA; Research Division, General Hospital of Mexico, Ciudad de Mexico, Mexico., Escobedo G; Research Division, General Hospital of Mexico, Ciudad de Mexico, Mexico., Navarro Olvera JL; Functional & Stereotactic Neurosurgery Unit, General Hospital of Mexico, Ciudad de Mexico, Mexico., Carrillo-Ruiz JD; Research Division, General Hospital of Mexico, Ciudad de Mexico, Mexico.; Functional & Stereotactic Neurosurgery Unit, General Hospital of Mexico, Ciudad de Mexico, Mexico.; Coordination of Neuroscience, Faculty of Psychology, University Anahuac Mexico, Huixquilucan, Mexico.
Jazyk:	angličtina
Zdroj:	Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme [Horm Metab Res] 2024 Feb; Vol. 56 (2), pp. 118-127. Date of Electronic Publication: 2023 Dec 11.
DOI:	10.1055/a-2209-0538
Abstrakt:	Pituitary adenomas are benign tumors of the anterior portion of the pituitary gland (adenohypophysis), representing the 25% of all the tumor alterations. Pituitary adenomas are classified by the type of hormone secreted, cellularity, size, and structural alterations by the hormonal segregation. The diagnosis consists on the histopathological identification of cell types and the image-guided by magnetic resonance or tomography; the treatment can be both pharmacological and surgical. Metabolic Syndrome is the set of clinical conditions that increase the risk of cardiovascular diseases with an estimated prevalence of 25% worldwide. The alterations of metabolic syndrome are obesity, hypertension, dyslipidemia, insulin resistance, and diabetes mellitus type II. Pituitary adenomas and metabolic syndrome have an important relationship, hormone-secreting by pituitary adenomas affects a myriad of signaling pathways, which allows a favorable environment for the appearance of the metabolic syndrome. Moreover, patients with pituitary adenomas are shown to have an improvement in metabolic parameters after the medical/surgical treatment. The objective of this review is to explore the possible mechanisms through which PAs contributes to MetSx. Competing Interests: The authors declare that they have no conflict of interest. (Thieme. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu